Targeted News Service

Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
May 09, 2025

NEW BRUNSWICK, New Jersey, May 9 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:

* * *

Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis

SPRING HOUSE, Pa. (May 9, 2025) - Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-TOTAL a study investigating icotrokinra (JNJ-2113), the first-in-class investigational targeted . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form